Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Down 35% This Year, Is This Small-Cap Stock a Buy?

TheMotleyFool

0 0

Down 35% This Year, Is This Small-Cap Stock a Buy?: https://g.foolcdn.com/editorial/images/690711/patient-talking-with-a-physician.jpg

Gene-editing specialist Editas Medicine (NASDAQ: EDIT) has had a challenging 2022, even compared to the struggling stock market. The company's shares are down 35% this year and nearly 60% over the past 12 months. If the company can turn things around, its recent struggles merely represent an opportunity to get in on a discount.

Before pressing the buy button, however, let's consider whether Editas Medicine has what it takes to rebound from its woes.